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Background
About 2% of the adult population worldwide is affected by 
chronic heart failure and this figure rises steeply with increasing 
age, especially from age 50, to about 10% in adults older than 
75 years of age.1 The life-time risk of developing heart failure at 
age 40 years is about 20% for both men and women.2 Ageing 
populations and improved treatment of acute cardiovascular 
events are contributing to the predicted 25% increase in heart 
failure in the next 20 years.3 Patients who suffer from heart failure 
have a poor overall prognosis and have high rates of hospital 
admissions and medical care costs. These facts necessitate that 
emphasis be placed on the prevention of heart failure as an 
important and critical health care issue.
Heart failure has many various causes and complicated patho-
physiological pathways, but essentially the greatest contributors 
to the risk of developing heart failure remain traditional 
cardiovascular risk factors which include hypertension, diabetes 
mellitus, elevated cholesterol, smoking, unhealthy life-style, 
obesity and lack of exercise.4 The development of heart failure 
generally proceeds in stages. Stage A: Risk factors are present 
but there are no symptoms or signs of heart failure. Stage B: 
There are still no symptoms or signs of heart failure but the 
heart has a structural abnormality such as left ventricular 
hypertrophy, previous myocardial infarction or a cardiac murmur 
and there could also be a functional cardiac abnormality such as 
asymptomatic reduction of the ejection fraction. Stage C: There 
are now symptoms and signs of heart failure. This is clinical heart 
failure.5 Once a patient has reached a specific stage, therapy 
cannot reverse the stage but can reduce the risk of progression.
Identify and treat Stage B heart failure
Preventative treatment with renin-angiotensin-aldosterone-
system (RAAS)-blockers is indicated in high-risk individuals 
without known ventricular dysfunction, in asymptomatic 
patients with known left ventricular systolic dysfunction, in 
people with recent myocardial infarction and left-ventricular 
dysfunction. Beta-blockers are also indicated post-myocardial 
infarction and left-ventricular dysfunction. 
Treatment of hypertension to prevent heart failure
Several meta-analyses have assessed heart failure endpoints 
in blood pressure lowering studies. In a large meta-analysis of 
approximately 1 million people in 61 prospective observational 
studies published in 2002, it was shown that long-term average 
reductions of 20 mmHg in usual systolic blood pressure halved 
the risk of heart failure mortality.6 The hazard ratio of 0.53 (95% 
CI: 0.48–0.59) in this study underscored the significant reduction 
in heart failure with a lower usual blood pressure. The absolute 
benefit of a lower blood pressure is likely to be greatest for those 
at a higher cardiovascular risk.
A 2014 meta-analysis of 68 randomised clinical trials involving 
235 885 participants showed that a reduction of 10 mmHg 
systolic and 5 mmHg diastolic blood pressure for 5 years was 
associated with a significant reduction of heart failure. The 
relative reduction in heart failure was 38% (95% CI: 25–49%) 
with an absolute risk reduction of 19 (95% CI: 13–24) per 1 000 
patients over 5 years, with a number needed-to-treat of 53 (95% 
CI: 49–79).7 The meta-analysis inclusion criteria were broad, 
as heart failure is not always an end-point in hypertension 
studies. In fact, of the 68, only 38 trials on hypertension could 
be included in this particular analysis. The authors also remarked 
that the reductions of heart failure as well as stroke were greater 
and more significant than any other cardiovascular outcome in 
these trials.
In 2016, another meta-analysis of 123 studies and 613 815 
hypertensive patients showed that for every 10 mmHg reduction 
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of systolic blood pressure, the relative risk of heart failure was 
reduced by 28% (95% CI: 22–33%).8 Unfortunately, absolute risk 
reductions were not calculated. 
Conversely, in a meta-analysis of 40 trials investigating blood 
pressure lowering in type 2 diabetes involving 100 354 
participants, the reduction of blood pressure did not lead to 
significant reductions in heart failure in diabetics.9 This un-
expected result could possibly be attributed to the smaller 
sample of randomised trials that evaluated heart failure as an 
end-point. Meanwhile, a 2018 meta-analysis of 74 trials and 306 
273 participants found it difficult to interpret the data on heart 
failure when outcomes based on baseline blood pressure values 
were assessed.10
Targeting people at high cardiovascular risk
Assessing cardiovascular risk is an important part of primary care, 
especially if early interventions are implemented successfully. 
Brain-type natriuretic peptide (BNP) screening of patients with 
cardiovascular risk factors and subsequent improved risk factor 
control and treatment with RAAS-inhibitors reduced the rate of 
asymptomatic left ventricular dysfunction or overt heart failure 
compared to normal (minimal) interventions.11 In patients with 
coronary artery disease without left ventricular dysfunction 
or heart failure, and in those patients with asymptomatic left 
ventricular dysfunction, regardless of aetiology, the use of RAAS-
inhibitors reduce the risk of hospital admissions due to heart 
failure.
Diabetes mellitus type-2
Type 2 diabetes mellitus (T2DM) is an important contributor 
to the development of heart failure. Usually, T2DM causes 
ischaemic heart disease, which leads to heart failure, but 
DM is also commonly associated with hypertension, and this 
combination is independently associated with an increased risk 
of heart failure. T2DM on its own is also associated with heart 
failure, a condition called diabetic cardiomyopathy. Interestingly, 
glycaemic control per se is not associated with a reduced risk of 
heart failure and some of the glitazones used as therapy may 
even lead to worsening heart failure.
Conversely, the sodium-glucose cotransporter-2 inhibitors (SGLT-
2 inhibitors) have been studied in T2DM and have consistently 
shown a reduction of hospitalisation for heart failure. A recent 
meta-analysis showed that the risk of hospitalisation for heart 
failure is reduced by a relative risk reduction of 23% (RR 0.77; 95% 
CI: 0.71–0.84; p < 0.0001) with a similar benefit in patients with 
and without atherosclerotic cardiovascular disease and with and 
without a history of heart failure.12
Role of statins
Statins have not really been evaluated carefully for their effect on 
heart failure, and the available data are sparse. There is, however, 
a publication suggesting that the use of statins may reduce the 
risk of heart failure.13
Lifestyle factors
Adherence to a healthy lifestyle, such as smoking cessation, 
regular exercise, healthy weight, moderate alcohol intake and 
consumption of high fibre and fruit and vegetables, is associated 
with a reduction in the risk of developing heart failure.14 Other 
studies have reported the same beneficial effects of a healthy 
lifestyle.
Concluding summary
1. Heart failure has a poor prognosis and can develop from 
virtually any cardiac condition.
2. Preventing heart failure is an important aspect of cardiovas-
cular practice and the high-risk patient should be identified in 
clinical practice for preventative therapy.
3. Proper treatment of hypertension with adequate control of 
blood pressure is probably the most important and significant 
aspect of preventing the development of heart failure.
4. Identifying others at high risk of developing heart failure, 
such as those surviving an atherosclerotic cardiac event, and 
treating them appropriately, reduces the risk of heart failure.
5. Attention to improving lifestyle factors should always be part 
of the prevention of heart failure over a lifetime as there is 
proven benefit.
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